Causes of mortality among inpatients with systemic lupus erythematosus in a tertiary care hospital in North India over a 10-year period, Lupus. févr, vol.22, issue.2, pp.216-238, 2013. ,
Mortality and Causes of Death of 513 Danish Patients with Systemic Lupus Erythematosus, Scandinavian Journal of Rheumatology, vol.40, issue.2, pp.75-80, 1999. ,
DOI : 10.1080/030097499442522
The causes of death in Korean patients with systemic lupus erythematosus over 11 years, Lupus, vol.42, issue.9, pp.989-97, 2011. ,
DOI : 10.1093/rheumatology/kep062
Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients, Annals of the Rheumatic Diseases, vol.68, issue.5, pp.658-63, 2009. ,
DOI : 10.1136/ard.2008.088302
Incidence, Risk Factors, and Outcome of Herpes Zoster in Systemic Lupus Erythematosus, JCR: Journal of Clinical Rheumatology, vol.16, issue.3, pp.119-141, 2010. ,
DOI : 10.1097/RHU.0b013e3181d52ed7
Les infections au cours du lupus syst??mique. Facteurs de risque et pronostic chez 87 patients, La Revue de M??decine Interne, vol.19, p.420, 1998. ,
DOI : 10.1016/S0248-8663(98)90105-9
White blood cell count abnormalities and infections in one-year follow-up of 124 patients with SLE EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, 103?7. 8. van Assen S414?22. 9. HAS. Calendrier des vaccinations et recommandations vaccinales HAS 2015 [Internet]. [cité 28 juin 2015]. Disponible sur, 2009. ,
A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized wegener's granulomatosis, Arthritis & Rheumatism, vol.38, issue.12, pp.2187-98, 1997. ,
DOI : 10.1002/art.1780401213
Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients, Arthritis & Rheumatism, vol.36, issue.4, pp.1186-97, 2010. ,
DOI : 10.1002/art.27340
Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review 29 mai 2015 Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry, Autoimmun Rev Terrier B Arthritis Rheum. août, vol.1462, issue.8, pp.2458-66, 2010. ,
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID) Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome, R75. 16. Díaz-Lagares CR112. 17. Edwards CJ672?6. 18. Cervera R, pp.299-308, 2003. ,
Mortality in systemic lupus erythematosus, Arthritis & Rheumatism, vol.51, issue.8, pp.2550-2557, 2006. ,
DOI : 10.1002/art.21955
Treatment of polyarteritis nodosa and Churg-Strauss syndrome. A meta-analysis of 3 prospective controlled trials including 182 patients over 12 years Longterm followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients, 405?16. 21. Gayraud M, pp.666-75, 1992. ,
Infectious complications of cyclophosphamide treatment for vasculitis, Arthritis & Rheumatism, vol.82, issue.1, pp.45-53, 1989. ,
DOI : 10.1002/anr.1780320108
Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodies-associated renal vasculitis: a 10-year retrospective study Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus, 343?9. 24. Ward MM, pp.664-70, 2000. ,
Infectious complications in systemic lupus erythematosus: a series of 146 patients]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, 626?31. 26. Ruiz-Irastorza G, 2008. ,
Predictors of major infections in systemic lupus erythematosus Rates of pneumococcal disease in adults with chronic medical conditions, Arthritis Res Ther. Open Forum Infect Dis. mars, vol.111, issue.271, p.24, 2009. ,
Glucocorticoid use, other associated factors, and the risk of tuberculosis):19?26. 29 Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases, 246?51. 30. Christian Michaux. Les complications infectieuses (hors infections à pyogènes), 1994. ,
Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy, J Rheumatol. juill, vol.31, issue.32, 2004. ,
Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement, Rheumatology International, vol.5, issue.11, pp.3373-82, 2012. ,
DOI : 10.1007/s00296-011-2151-0
Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a literature review, Rheumatology, vol.46, issue.3, pp.539-583, 2007. ,
DOI : 10.1093/rheumatology/kel343
Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry Rate of serious infections in Behçet's disease patients receiving biologic therapies: a prospective observational study, 1475?82. 36. Terrier B, pp.1547-1555, 1996. ,
Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis, 268?74. 39, pp.416-439, 2009. ,
Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy, e78699. 42. Mowlah I. Profil de tolérance au long cours du rituximab prescrit dans les maladies immuno-inflkammatoires. Mémoire pour l'obtention du Diplôme de formation médicale spécialisée en médecine interne, pp.799-805, 2012. ,
Increased risk of Pneumocystis carinii pneumonia in patients with Wegener's granulomatosis, Clin Exp Rheumatol. déc, vol.11, issue.6, pp.615-636, 1993. ,
Human Papillomavirus Vaccine in Patients with Systemic Lupus Erythematosus, Epidemiology, vol.25, issue.1, pp.155-161, 2014. ,
DOI : 10.1097/EDE.0000000000000033
A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: Safety and immunity, Vaccine, vol.29, issue.3, pp.444-50, 2011. ,
DOI : 10.1016/j.vaccine.2010.10.081
A controlled study of pneumococcal polysaccharide vaccine in systemic lupus erythematosus Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives, ):1068?73. 47, pp.1321-1326, 1979. ,
Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity, The Journal of Rheumatology, vol.40, issue.11, pp.1875-80, 2013. ,
DOI : 10.3899/jrheum.130170
Hepatitis B vaccination of SLE patients Proceedings of the ACR Congress Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab, 623?5. 52. Gelinck LBS, pp.1402-1405, 1996. ,
Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations Clin Infect Dis Off Publ Infect Dis Soc Am. 15 août Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity, Arch Intern Med. 14 sept J Rheumatol. juill Battafarano DF, vol.3515827, issue.557, pp.1681-1686, 1998. ,
Antigen-specific antibody responses in lupus patients following immunization, Arthritis Rheum. oct, vol.41, issue.10, 1998. ,
Safety of vaccination of patients with systemic lupus erythematosus, Lupus, vol.18, issue.13 ,
DOI : 10.1177/0961203309346507
Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies):493?6. 60 High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus):1121?7. 61. Rolland ludivine. Evaluation des pratiques de prévention anti-infectieuses chez les personnes traitées par immunosuppresseurs pour une maladie immuno, Autoimmunity. nov Arthritis Care Res. juill, vol.183865, issue.5977, p.62, 2005. ,
EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis, Annals of the Rheumatic Diseases, vol.69, issue.10 ,
DOI : 10.1136/ard.2009.119032
Traité des maladies et syndromes systémiques. 5ème édition. Paris: Flammarion médecine-sciences, 2008. ,
Preliminary criteria for the classification of Sj??gren's syndrome. Results of a prospective concerted action supported by the European community, Arthritis & Rheumatism, vol.10, issue.3, pp.340-347, 1993. ,
DOI : 10.1002/art.1780360309
Validity and reliability of lupus activity measures in the routine clinic setting, J Rheumatol. janv Amezcua-Guerra LM, vol.19, issue.70, 1992. ,
Systemic Lupus International Collaborating Clinics and the 1997 American College of Rheumatology classification criteria for systemic lupus erythematosus in a real-life scenario):437?41. 71. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease, Arthritis Care Res. mars Lancet Lond Engl. 5 mai, vol.67335, issue.38697, pp.1078-80, 1990. ,
The saga of diagnostic/classification criteria in Behcet's disease International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD) The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria Classification criteria of Sjögren's syndrome, ):594?605. 73338?47. 74. Goules AV, Tzioufas AG, Moutsopoulos HM, pp.48-4942, 2014. ,
Colchicine versus placebo in Beh??et???s disease: randomized, double-blind, controlled crossover trial, Modern Rheumatology, vol.43, issue.5, pp.542-551, 2009. ,
DOI : 10.3109/s10165-009-0200-2
Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study, J Rheumatol. janv, vol.32, issue.1, pp.98-105, 2005. ,
Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1528-1562, 2009. ,
DOI : 10.1136/ard.2008.087957
American College of Rheumatology classification criteria for Sjögren's syndrome: a datadriven , expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort, 475?87. 79. Devauchelle-Pensec V, pp.233-275, 2012. ,
Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sj??gren Syndrome, JAMA, vol.312, issue.3, pp.249-58, 2014. ,
DOI : 10.1001/jama.2014.7682
Diagnosis and classification of immune-mediated thrombocytopenia, Autoimmunity Reviews, vol.13, issue.4-5 ,
DOI : 10.1016/j.autrev.2014.01.026
Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the The American Society of Hematology ITP Practice Guideline Panel evidence-based practice guideline for immune thrombocytopenia Treatment practices in adults with chronic immune thrombocytopenia ? a European perspective, Ann Intern Med. 15 févr Blood. 21 avr Eur J Haematol. 1 févr, vol.12611784, issue.842, pp.319-345, 1997. ,
Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. The Lancet, 395?403. 87. Kuter DJ, 2008. ,
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. The Lancet Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura, 393?402. 89. Bussel JB, pp.2237-2284, 2007. ,
Anémies hémolytiques autoimmunes Protocole national de diagnostic et de soins Guide des affections longue durée HAS ,
The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases Antiphospholipid-associated thrombocytopenia or autoimmune hemolytic anemia in patients with or without definite primary antiphospholipid syndrome according to the Sapporo revised classification criteria: a 6-year follow-up study A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia, 3167?72. 92. Comellas-3058?63. 93. Birgens H, pp.393-402, 2009. ,
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients, Blood, vol.124, issue.19, pp.2930-2936, 2014. ,
DOI : 10.1182/blood-2014-06-583021
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, Arthritis & Rheumatism, vol.7, issue.7, pp.1309-1320, 1999. ,
DOI : 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F
Validation of the Sapporo criteria for antiphospholipid syndrome, Arthritis & Rheumatism, vol.43, issue.2, pp.440-443, 2000. ,
DOI : 10.1002/1529-0131(200002)43:2<440::AID-ANR26>3.0.CO;2-N
Nouvelles classifications et??physiopathologie des??myopathies inflammatoires, La Revue de M??decine Interne, vol.28, issue.9, pp.603-615, 2007. ,
DOI : 10.1016/j.revmed.2007.03.004
Unicorns, dragons, polymyositis, and other mythological beasts, Neurology, vol.61, issue.3, pp.288-297, 2003. ,
DOI : 10.1212/WNL.61.3.288
Polymyositis and Dermatomyositis, New England Journal of Medicine, vol.292, issue.7, pp.344-351, 1975. ,
DOI : 10.1056/NEJM197502132920706
Polymyositis, Neurology, vol.61, issue.3, pp.316-337, 2003. ,
DOI : 10.1212/WNL.61.3.316
Evolution des taux plasmatiques des LDH (lacticodeshydrog??nase), CPK (cr??atine phosphokinase) et de la myoglobine ?? l'issue d'une course de 100 km et d'un triathlon, Science & Sports, vol.1, issue.3, pp.255-63, 1986. ,
DOI : 10.1016/S0765-1597(86)80007-7
193rd ENMC International workshop Pathology diagnosis of idiopathic inflammatory myopathies 30 November ??? 2 December 2012, Naarden, The Netherlands, Neuromuscular Disorders, vol.23, issue.11, pp.945-51, 2012. ,
DOI : 10.1016/j.nmd.2013.07.007
Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria, Clin Exp Rheumatol. oct, vol.31, issue.5, pp.767-776, 2013. ,
Classification criteria for the idiopathic inflammatory myopathies, Current Opinion in Rheumatology, vol.9, issue.6, pp.527-562, 1997. ,
DOI : 10.1097/00002281-199711000-00008
Polymyositis and dermatomyositis. The Lancet, pp.971-82, 2003. ,
119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, Neuromuscul Disord. mai, vol.1014, issue.5, pp.337-382, 2003. ,
Redefining Dermatomyositis, Medicine, vol.93, issue.24, pp.318-350, 2014. ,
DOI : 10.1097/MD.0000000000000222
URL : http://doi.org/10.1097/md.0000000000000222
Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies, Medicine, vol.84, issue.4, pp.231-280, 2005. ,
DOI : 10.1097/01.md.0000173991.74008.b0
Ph??notypes cliniques et pronostic du syndrome des antisynth??tases, La Revue de M??decine Interne, vol.35, issue.7, pp.453-60, 2014. ,
DOI : 10.1016/j.revmed.2013.09.003
The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis, Rheumatology, vol.54, issue.1, pp.39-44, 2015. ,
DOI : 10.1093/rheumatology/keu166
Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial, Modern Rheumatology, vol.44, issue.3, pp.382-93, 2012. ,
DOI : 10.1056/NEJM199312303292704
Resistive Home Exercise in Patients with Recent-onset Polymyositis and Dermatomyositis -- A Randomized Controlled Single-blinded Study with a 2-year Followup, The Journal of Rheumatology, vol.41, issue.6, pp.1124-1156, 2014. ,
DOI : 10.3899/jrheum.131145
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies, Arthritis & Rheumatism, vol.38, issue.9, pp.2607-2622, 2005. ,
DOI : 10.1002/art.21291
Les manifestations pulmonaires du syndrome des antisynth??tases, Revue des Maladies Respiratoires, vol.32, issue.6, pp.618-646, 2015. ,
DOI : 10.1016/j.rmr.2014.07.013
URL : http://dx.doi.org/10.1016/j.rmr.2014.07.013
Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies, Internal Medicine Journal, vol.70, issue.9, pp.674-683, 2011. ,
DOI : 10.1111/j.1445-5994.2010.02164.x
Les crit??res diagnostiques de la maladie de Takayasu, La Revue de M??decine Interne, vol.30, pp.255-262, 2009. ,
DOI : 10.1016/j.revmed.2009.09.005
Diagnostic criteria for Takayasu arteritis, International Journal of Cardiology, vol.54, pp.127-160, 1996. ,
DOI : 10.1016/0167-5273(96)02647-2
The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease, European Journal of Nuclear Medicine and Molecular Imaging, vol.43, issue.Suppl 2, pp.674-81, 2005. ,
DOI : 10.1007/s00259-004-1757-9
Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study, Rheumatology, vol.51, issue.5, pp.882-888, 2012. ,
DOI : 10.1093/rheumatology/ker380
Purpura rhumato??de de l???adulte, La Revue de M??decine Interne, vol.35, issue.6, pp.372-81, 2014. ,
DOI : 10.1016/j.revmed.2013.12.004
The American College of Rheumatology 1990 criteria for the classification of henoch-sch??nlein purpura, Arthritis & Rheumatism, vol.33, issue.8, pp.1114-1135, 1990. ,
DOI : 10.1002/art.1780330809
PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis, 2008. ,
The American College of Rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis), Arthritis & Rheumatism, vol.56, issue.8, pp.1094-100, 1990. ,
DOI : 10.1002/art.1780330806
The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosis, Arthritis & Rheumatism, vol.19, issue.8, pp.1101-1108, 1990. ,
DOI : 10.1002/art.1780330807
A comparison of two nomenclature systems for primary systemic vasculitis, Rheumatology, vol.36, issue.4, pp.453-461, 1997. ,
DOI : 10.1093/rheumatology/36.4.453
Nomenclature of Systemic Vasculitides, Arthritis & Rheumatism, vol.91, issue.2, pp.187-92, 1994. ,
DOI : 10.1002/art.1780370206
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, pp.1-11, 2012. ,
DOI : 10.1002/art.37715
The diagnosis and classification of microscopic polyangiitis, Journal of Autoimmunity, vol.48, issue.49, pp.48-4990, 2014. ,
DOI : 10.1016/j.jaut.2014.01.023
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis, Annals of the Rheumatic Diseases, vol.66, issue.5, pp.605-622, 2007. ,
DOI : 10.1136/ard.2006.062711
Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), Arthritis Research & Therapy, vol.15, issue.5, p.133, 2013. ,
DOI : 10.1016/j.jaci.2010.02.026
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis, New England Journal of Medicine, vol.371, issue.19, pp.1771-80, 2014. ,
DOI : 10.1056/NEJMoa1404231
URL : https://hal.archives-ouvertes.fr/hal-01116525
Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients, Arthritis & Rheumatism, vol.345, issue.1, pp.308-325, 2008. ,
DOI : 10.1002/art.23147
Biologic and clinical significance of cryoglobulins, The American Journal of Medicine, vol.57, issue.5, pp.775-88, 1974. ,
DOI : 10.1016/0002-9343(74)90852-3
Preliminary classification criteria for the cryoglobulinaemic vasculitis, Annals of the Rheumatic Diseases, vol.70, issue.7, pp.1183-90, 2011. ,
DOI : 10.1136/ard.2011.150755
Validation of the classification criteria for cryoglobulinaemic vasculitis, Rheumatology, vol.53, issue.12, pp.2209-2222, 2014. ,
DOI : 10.1093/rheumatology/keu271
Wegener's granulomatosis. Anatomic correlates, a proposed classification, Mayo Clin Proc. déc, vol.51, issue.12, pp.777-81, 1976. ,
What do we mean by validating a prognostic model?, Statistics in Medicine, vol.130, issue.4, pp.453-73, 2000. ,
DOI : 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome, Annals of the Rheumatic Diseases, vol.69, issue.6, pp.1103-1112, 2010. ,
DOI : 10.1136/ard.2009.110619
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease, Rheumatology, vol.43, issue.1, pp.49-54, 2004. ,
DOI : 10.1093/rheumatology/keg427
Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies, Rheumatology, vol.40, issue.11, pp.1262-73, 2001. ,
DOI : 10.1093/rheumatology/40.11.1262
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials, The Journal of Rheumatology, vol.38, issue.11, pp.2395-2404, 2011. ,
DOI : 10.3899/jrheum.110550
Le rituximab dans l???indication ????n??phropathie lupique??????: ??tude r??trospective du CHU de Bordeaux, France, La Revue de M??decine Interne, vol.33, issue.2, pp.83-87, 2012. ,
DOI : 10.1016/j.revmed.2012.10.117
Caract??ristiques et modalit??s ??volutives du purpura thrombop??nique idiopathique multir??fractaire en 2014??: analyse de 26??observations, La Revue de M??decine Interne, vol.35, issue.2, pp.86-93, 2014. ,
DOI : 10.1016/j.revmed.2014.10.138
Utilisation r??p??t??e du rituximab dans le traitement des thrombop??nies auto-immunes??: ??tude monocentrique sur 12??cas, La Revue de M??decine Interne, vol.32, p.50, 2011. ,
DOI : 10.1016/j.revmed.2011.03.030
Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients, Lupus, vol.31, issue.8, pp.638-682, 1999. ,
DOI : 10.1191/096120399680411443
Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus, New England Journal of Medicine, vol.353, issue.24, pp.2550-2558, 2005. ,
DOI : 10.1056/NEJMoa051135
Systemic lupus erythematosus disease activity index 2000, J Rheumatol. févr, vol.29, issue.2, pp.288-91, 2002. ,
From BILAG to BLIPS???disease activity assessment in lupus past, present and future, Lupus, vol.9, issue.9, pp.651-655, 2000. ,
DOI : 10.1191/096120300672904669
Classification and definition of major flares in SLE clinical trials, Lupus, vol.26, issue.2, pp.685-91, 1999. ,
DOI : 10.1191/096120399680411281
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus, Rheumatology, vol.44, issue.7, pp.902-908, 2004. ,
DOI : 10.1093/rheumatology/keh624
Definition and treatment of lupus flares measured by the BILAG index, Rheumatology, vol.42, issue.11, pp.1372-1381, 2003. ,
DOI : 10.1093/rheumatology/keg382
BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000, Annals of the Rheumatic Diseases, vol.67, issue.6, pp.873-879, 2008. ,
DOI : 10.1136/ard.2007.070847
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity, Rheumatology, vol.48, issue.6, pp.691-696, 2009. ,
DOI : 10.1093/rheumatology/kep064
Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research, Arthritis Research & Therapy, vol.20, issue.1, p.183, 2015. ,
DOI : 10.1186/s13075-015-0702-6
The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment, Autoimmunity Reviews, vol.11, issue.5, pp.326-335, 2012. ,
DOI : 10.1016/j.autrev.2011.06.011
Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE, Clin Exp Rheumatol. oct, vol.10, issue.5, pp.541-548, 1992. ,
The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus, Lupus, vol.1, issue.1, pp.445-50, 2000. ,
DOI : 10.1191/096120300678828640
The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus, Q J Med. juill, vol.86, issue.7, pp.447-58, 1993. ,
A review on disease activity scores in Behçet's disease (BD), Arthritis Research & Therapy, vol.5, issue.Suppl 2, p.7, 2003. ,
DOI : 10.1186/ar982
Behcet's disease: evaluation of a new instrument to measure clinical activity, Rheumatology, vol.38, issue.8, pp.728-761, 1999. ,
DOI : 10.1093/rheumatology/38.8.728
The Behcet's Disease Activity Index, Rheumatology, vol.43, issue.1, pp.73-81, 2004. ,
DOI : 10.1093/rheumatology/keg453
Outcome Measures Used in Clinical Trials for Behcet Syndrome: A Systematic Review, The Journal of Rheumatology, vol.41, issue.3, pp.599-612, 2014. ,
DOI : 10.3899/jrheum.131249
Outcome Measures Used in Clinical Trials for Behcet Syndrome: A Systematic Review, The Journal of Rheumatology, vol.41, issue.3, pp.599-612, 2014. ,
DOI : 10.3899/jrheum.131249
Primary Sj??gren???s syndrome activity and damage indices comparison, European Journal of Clinical Investigation, vol.44, issue.31 Suppl, pp.636-680, 2010. ,
DOI : 10.1111/j.1365-2362.2010.02303.x
Clinimetric methods in Sj??gren's syndrome, Seminars in Arthritis and Rheumatism, vol.42, issue.6, pp.627-666, 2013. ,
DOI : 10.1016/j.semarthrit.2012.09.008
Sjogren's Systemic Clinical Activity Index (SCAI) a systemic disease activity measure for use in clinical trials in primary Sjogren's syndrome, Rheumatology, vol.46, issue.12, pp.1845-51, 2007. ,
DOI : 10.1093/rheumatology/kem280
Outcome measures for primary Sj??gren???s syndrome, Journal of Autoimmunity, vol.39, issue.1-2, pp.97-102, 2012. ,
DOI : 10.1016/j.jaut.2012.01.013
Sj??gren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sj??gren's syndrome, derived from an analysis of a cohort of Italian patients, Arthritis & Rheumatism, vol.2, issue.7, pp.2223-2254, 2007. ,
DOI : 10.1002/art.22658
European League Against Rheumatism Sj??gren's Syndrome Disease Activity Index and European League Against Rheumatism Sj??gren's Syndrome Patient-Reported Index: A Complete Picture of Primary Sj??gren's Syndrome Patients, Arthritis Care & Research, vol.63, issue.8, pp.1358-64, 2013. ,
DOI : 10.1002/acr.21991
Accurate detection of changes in disease activity in primary Sj??gren's syndrome by the European League Against Rheumatism Sj??gren's Syndrome Disease Activity Index, Arthritis Care & Research, vol.29, issue.4, pp.551-559, 2010. ,
DOI : 10.1002/acr.20173
Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry), Rheumatology, vol.53, issue.2, pp.321-352, 2014. ,
DOI : 10.1093/rheumatology/ket349
United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings, British Journal of Haematology, vol.90, issue.4, pp.590-594, 2015. ,
DOI : 10.1111/bjh.13330
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group, Blood, vol.113, issue.11, pp.2386-93, 2009. ,
DOI : 10.1182/blood-2008-07-162503
How I treat autoimmune hemolytic anemias in adults, Blood, vol.116, issue.11, pp.1831-1839, 2010. ,
DOI : 10.1182/blood-2010-03-259325
purpura thombopenique immunologique de l'enfant et d l'adulte Protocole national de diagnostic et de soins Guide des affections longue durée HAS. oct, 2009. ,
Bleeding Signs in Children With Idiopathic Thrombocytopenic Purpura, Journal of Pediatric Hematology/Oncology, vol.25, issue.Supplement 1, pp.42-48, 2003. ,
DOI : 10.1097/00043426-200312001-00010
Determination of bleeding risk in thrombocytopenic patients with platelet transfusion therapy ,
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP, British Journal of Haematology, vol.35, issue.Suppl. 1, pp.245-253, 2007. ,
DOI : 10.1111/j.1365-2141.2007.06635.x
Muscles: Testing and function. 4ème édition. Williams and Wilkins, 1993. ,
Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies, Arthritis Care & Research, vol.10, issue.4, pp.465-72, 2010. ,
DOI : 10.1002/acr.20035
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease, Rheumatology, vol.43, issue.1, pp.49-54, 2004. ,
DOI : 10.1093/rheumatology/keg427
Defining Clinical Improvement in Adult and Juvenile Myositis, J Rheumatol. 3 janv, vol.30, issue.3, pp.603-620, 2003. ,
Prise en charge thérapeutique des polymyosites, dermatomyosites, myosites de chevauchement et myopathies nécrosantes auto-immunes. Rev Médecine Interne, juill, vol.35, issue.7, pp.466-71, 2014. ,
International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies, Arthritis & Rheumatism, vol.38, issue.9, pp.2607-2622, 2005. ,
DOI : 10.1002/art.21291
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis, QJM Mon J Assoc Physicians. nov, vol.87, issue.11, pp.671-679, 1994. ,
Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis, J Rheumatol, vol.32, issue.12, pp.2488-95, 2005. ,
Development and validation of a disease extent index for Wegener's granulomatosis, Clin Nephrol. janv, vol.55, issue.1, pp.31-39, 2001. ,
Modification and validation of the Birmingham Vasculitis Activity Score (version 3), Annals of the Rheumatic Diseases, vol.68, issue.12, pp.1827-1859, 2009. ,
DOI : 10.1136/ard.2008.101279
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis, Rheumatology, vol.50, issue.5, pp.899-905, 2011. ,
DOI : 10.1093/rheumatology/keq400
Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial, Trials, vol.14, issue.1, p.73, 2013. ,
DOI : 10.1016/j.ymgme.2008.10.003
Rituximab With or Without a Conventional Maintenance Agent in the Treatment of Relapsing Granulomatosis With Polyangiitis (Wegener's): A Retrospective Single-Center Study, Arthritis & Rheumatology, vol.64, issue.Suppl, pp.2862-70, 2014. ,
DOI : 10.1002/art.38744
Prognostic Factors in Polyarteritis Nodosa and Churg-Strauss Syndrome A Prospective Study in 342 Patients, Medicine, vol.75, issue.1, pp.17-28, 1996. ,
DOI : 10.1097/00005792-199601000-00003
vascularites nécrosantes systémiques Protocole national de diagnostic et de soins Guide des affections longue durée HAS, 2007. ,
Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: A prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients, Arthritis Care & Research, vol.112, issue.Suppl 9, pp.93-100, 2003. ,
DOI : 10.1002/art.10922
Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors, Autoimmunity Reviews, vol.13, issue.9, pp.945-53, 2014. ,
DOI : 10.1016/j.autrev.2014.08.002
The Five-Factor Score Revisited, Medicine, vol.90, issue.1, pp.19-27, 2011. ,
DOI : 10.1097/MD.0b013e318205a4c6
Validity of a vasculitis activity index for systemic necrotizing vasculitis, Arthritis & Rheumatism, vol.9, issue.11, pp.2365-71, 1999. ,
DOI : 10.1002/1529-0131(199911)42:11<2365::AID-ANR15>3.0.CO;2-M
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, Annals of the Rheumatic Diseases, vol.68, issue.1, pp.103-109, 2009. ,
DOI : 10.1136/ard.2008.097758
Demographic, clinical, and angiographic data of patients with Takayasu arteritis in Brazil, International Journal of Cardiology, vol.66, 1998. ,
DOI : 10.1016/S0167-5273(98)00152-1
Group for the I. Op14. the Indian Perspective of Takayasu Arteritis and Development of a Disease Extent Index (dei.tak) to Assess Takayasu Arteritis, Rheumatology. 7 janv, vol.44, issue.3, pp.6-7, 2005. ,
Takayasu Arteritis, Annals of Internal Medicine, vol.120, issue.11, pp.919-948, 1994. ,
DOI : 10.7326/0003-4819-120-11-199406010-00004
Clinical outcomes in children with Henoch???Sch??nlein purpura nephritis grade IIIa or IIIb, Pediatric Nephrology, vol.49, issue.7, pp.1083-1091, 2011. ,
DOI : 10.1007/s00467-011-1834-9
Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy, Clin Nephrol. janv, vol.49, issue.1, pp.9-14, 1998. ,
Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP), Archives of Disease in Childhood, vol.94, issue.10, pp.756-63, 2013. ,
DOI : 10.1136/archdischild-2013-303642
Treatment of Henoch-Sch??nlein Purpura Glomerulonephritis in Children with High-Dose Corticosteroids plus Oral Cyclophosphamide, American Journal of Nephrology, vol.21, issue.2, pp.128-161, 2001. ,
DOI : 10.1159/000046235
Effects of Chinese herbs in children with Henoch-Schonlein purpura nephritis: a randomized controlled trial, Journal of Traditional Chinese Medicine, vol.34, issue.1, pp.15-22, 2014. ,
DOI : 10.1016/S0254-6272(14)60048-0
Cyclosporine A vs. methylprednisolone for Henoch???Sch??nlein nephritis: a randomized trial, Pediatric Nephrology, vol.40, issue.12, pp.2159-66, 2011. ,
DOI : 10.1007/s00467-011-1919-5
Cyclosporin A for the treatment of severe Henoch-Sch???nlein glomerulonephritis, Pediatric Nephrology, vol.18, issue.11, pp.1138-1180, 2003. ,
DOI : 10.1007/s00467-003-1245-7
Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study, Archives of Disease in Childhood, vol.95, issue.11, pp.871-877, 2010. ,
DOI : 10.1136/adc.2009.167874
Early prednisone therapy in Henoch-Sch??nlein purpura: A randomized, double-blind, placebo-controlled trial, The Journal of Pediatrics, vol.149, issue.2, pp.241-248, 2006. ,
DOI : 10.1016/j.jpeds.2006.03.024
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI) Ann Rheum Dis, 2014. ,
Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus, Arthritis & Rheumatism, vol.28, issue.9, pp.1107-1125, 1989. ,
DOI : 10.1002/anr.1780320909
Diagnostic error and clinical reasoning, Medical Education, vol.41, issue.1, pp.94-100, 2010. ,
DOI : 10.1111/j.1365-2923.2009.03507.x
Diagnostic reasoning in neurology An analysis of the more frequent errors], Neurol Barc Spain. déc, vol.18, issue.2, pp.3-10, 2003. ,
Heuristics and biases - a biased perspective on clinical reasoning, Medical Education, vol.74, issue.7, pp.870-872, 2005. ,
DOI : 10.1207/S1532690XCI1704_3
De la subjectivité sociétale d'un déni de la subjectivité individuelle à la perception subjective des diagnostics en pratique clinique : la possibilité partielle d'un diagnostic standardisé de cette perception ,
Éducation et qualité de la décision médicale : un lien fondé sur des preuves existe-t-il ? Rev Médecine Interne, juill, vol.32, issue.7, pp.436-478, 2011. ,
Overconfidence in Clinical Decision Making, The American Journal of Medicine, vol.121, issue.5, pp.24-33, 2008. ,
DOI : 10.1016/j.amjmed.2008.02.001
Le praticien enrichit-il sa compétence en s'ouvrant à sa propre subjectivité ? Médecine Palliat Soins Support -Accompagnement -Éthique, avr, vol.7, issue.2, pp.98-103, 2008. ,
Translating Clinical Research into Clinical Practice: Impact of Using Prediction Rules To Make Decisions, Annals of Internal Medicine, vol.144, issue.3, pp.201-210, 2006. ,
DOI : 10.7326/0003-4819-144-3-200602070-00009
Disponible sur: http://data.over-blog-kiwi.com/0 A Randomized Study of How Physicians Interpret Research Funding Disclosures, N Engl J Med, vol.841743367, issue.12, pp.1119-1146, 1968. ,
Perception par les m??decins internistes de la fr??quence et de la g??ne induite par les effets ind??sirables d???une corticoth??rapie syst??mique prolong??e, La Revue de M??decine Interne, vol.30, issue.2, pp.113-121, 2009. ,
DOI : 10.1016/j.revmed.2008.08.004
Asthma control in general practice: a cross-sectional survey of 16,580 patients]. Presse Médicale Paris Fr, 1983. ,
Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity, J Rheumatol. mars, vol.27, issue.3, pp.675-684, 2000. ,
Frequency of Inappropriate Medical Exceptions to Quality Measures, Annals of Internal Medicine, vol.152, issue.4, pp.225-256, 2010. ,
DOI : 10.7326/0003-4819-152-4-201002160-00007
Different Measures, Different Outcomes? A Systematic Review of Performance-Based versus Self-Reported Measures of Health Literacy and Numeracy, Journal of General Internal Medicine, vol.27, issue.1, 2015. ,
DOI : 10.1007/s11606-015-3288-4
La perception du risque': Théories et données empiriques, Rev Sci Soc, issue.38, pp.20-29, 2007. ,
Risk perceptions of offshore workers on UK oil and gas platforms. Risk Anal Off Publ Soc Risk Anal, févr, vol.18, issue.1, pp.103-113, 1998. ,
Abstract, Infection Control & Hospital Epidemiology, vol.41, issue.06, pp.456-464, 2003. ,
DOI : 10.2165/00002512-199710030-00003
Effects of the feeling of invulnerability and the feeling of control on motivation to participate in experience-based analysis, by type of risk, Accident Analysis & Prevention, vol.51, pp.310-317, 2013. ,
DOI : 10.1016/j.aap.2012.11.026
Recommandations concernant la prise en charge thérapeutique et suivi des Spondylarthrite Disponible sur: http://www.has-sante.fr/portail Polyarthrite rhumatoide Recommandations prise en charge initiale [Internet], Disponible sur, 2007. ,
Effective handover communication: An overview of research and improvement efforts, Best Practice & Research Clinical Anaesthesiology, vol.25, issue.2, pp.181-91, 2011. ,
DOI : 10.1016/j.bpa.2011.02.006
Making the Case for Investigating Flexibility in Duty Hour Limits for Surgical Residents, JAMA Surgery, vol.150, issue.6, pp.503-507, 2015. ,
DOI : 10.1001/jamasurg.2015.0239
Factors influencing the implementation of clinical guidelines for health care professionals: A systematic meta-review, BMC Medical Informatics and Decision Making, vol.115, issue.Suppl 2 ,
DOI : 10.1111/j.1600-0447.2007.01016.x
Breaking the rules: understanding non-compliance with policies and guidelines, BMJ, vol.343, issue.sep13 3, p.5283, 2011. ,
DOI : 10.1136/bmj.d5283
Deuxième édition 1950 Quadrige/ Puf, 2006. ,